Muhimbili University of Health and Allied Sciences
Institutional Repository

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations

Show simple item record

dc.contributor.author Ngaimisi, E.,
dc.contributor.author Habtewold, A.
dc.contributor.author Minzi, O.
dc.contributor.author Makonnen, E.
dc.contributor.author Mugusi, S.
dc.contributor.author Amogne, W.
dc.contributor.author Yimer, G
dc.contributor.author Riedel, K
dc.contributor.author Janabi, M
dc.contributor.author Aderaye, G
dc.contributor.author Mugusi, F
dc.contributor.author Bertilsso, L
dc.contributor.author Aklillu, E
dc.contributor.author Burhenne, J
dc.date.accessioned 2014-11-18T08:26:46Z
dc.date.available 2014-11-18T08:26:46Z
dc.date.issued 2013-07-05
dc.identifier.citation Ngaimisi, E., Habtewold, A., Minzi, O., Makonnen, E., Mugusi, S., Amogne, W., ... & Burhenne, J. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PloS one, 8(7), e67946. en_GB
dc.identifier.uri http://hdl.handle.net/123456789/1486
dc.description.abstract Objectives: We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations. Methods: ART naı¨ve HIV patients from Ethiopia (n = 285) and Tanzania (n = 209) were prospectively enrolled in parallel to start efavirenz based HAART. CD4+ cell counts were determined at baseline, 12, 24 and 48 weeks. Plasma and intracellular efavirenz and 8-hydroxyefvairenz concentrations were determined at week 4 and 16. Genotyping for common functional CYP2B6, CYP3A5, ABCB1, UGT2B7 and SLCO1B1 variant alleles were done. Result: Patient country, CYP2B6*6 and ABCB1 c.4036A.G (rs3842A.G) genotype were significant predictors of plasma and intracellular efavirenz concentration. CYP2B6*6 and ABCB1 c.4036A.G (rs3842) genotype were significantly associated with higher plasma efavirenz concentration and their allele frequencies were significantly higher in Tanzanians than Ethiopians. Tanzanians displayed significantly higher efavirenz plasma concentration at week 4 (p,0.0002) and week 16 (p = 0.006) compared to Ethiopians. Efavirenz plasma concentrations remained significantly higher in Tanzanians even after controlling for the effect of CYP2B6*6 and ABCB1 c.4036A.G genotype. Within country analyses indicated a significant decrease in the mean plasma efavirenz concentration by week 16 compared to week 4 in Tanzanians (p = 0.006), whereas no significant differences in plasma concentration over time was observed in Ethiopians (p = 0.84). Intracellular efavirenz concentration and patient country were significant predictors of CD4 gain during HAART. Conclusion: We report substantial differences in efavirenz pharmacokinetics, extent of auto-induction and immunologic recovery between Ethiopian and Tanzanian HIV patients, partly but not solely, due to pharmacogenetic variations. The observed inter-ethnic variations in efavirenz plasma exposure may possibly result in varying clinical treatment outcome or adverse event profiles between populations. en_GB
dc.language.iso en en_GB
dc.publisher PloS one en_GB
dc.relation.ispartofseries PloS one, 8(7), e67946.;
dc.title Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations en_GB
dc.type Article en_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MUHAS Repository


Advanced Search MUHAS Repository

Browse

My Account